Core Thesis - Abbott Laboratories (ABT) is viewed positively due to its diversified healthcare model, strong market position in medical devices, and consistent dividend growth, despite facing near-term challenges [1][6]. Company Overview - Abbott Laboratories is a global healthcare company involved in medical devices, diagnostics, nutrition, and established pharmaceuticals, with nearly 70% of its revenue coming from medical devices and diagnostics [3]. - Key products include the FreeStyle Libre glucose monitor and heart repair devices, which contribute to a competitive advantage through patents and high switching costs [3]. Financial Performance - As of March 6th, ABT's share price was $109.56, with trailing and forward P/E ratios of 29.45 and 19.30, respectively [1]. - The company has a strong balance sheet, featuring a debt-to-equity ratio of 30% and an interest coverage ratio of 75, alongside robust free cash flow generation [5]. - Abbott has maintained a dividend growth streak of 54 consecutive years, with a 5-year compound annual growth rate (CAGR) of 9.4% [5]. Market Challenges - Abbott faces several near-term challenges, including legal liabilities related to specialty infant formula, weakened demand post-price increases, declining COVID-testing revenues, and pricing pressures in China, contributing to a stock decline of approximately 15% this year [4]. - The dividend yield has approached 2.4% due to these pressures [4]. Long-term Outlook - Despite current headwinds, Abbott is well-positioned for long-term growth due to favorable trends in chronic disease management, an aging population, and emerging middle-class markets [5]. - The company's management, led by CEO Robert B. Ford, has a proven track record in navigating complex markets and executing acquisitions, such as the $21 billion Exact Sciences deal aimed at cancer diagnostics [4][5]. - For long-term investors, Abbott represents a compelling opportunity with a mix of defensive characteristics and innovation-driven growth potential [6].